RA Session II | President, Chief Executive Officer & Founder |
Kimberly Lee | Corporate Affairs Officer |
Suyash Prasad | Chief Medical Officer & Head, Research & Development |
Kamran Alam | Chief Financial Officer |
Elizabeth Webster | Goldman Sachs |
Joon Lee | Truist Securities |
Mike Ulz | Morgan Stanley |
Jack Allen | Baird |
Kevin DeGeeter | Oppenheimer |
Gil Blum | Needham and Company |
Laura Chico | Wedbush Securities |
Yun Zhong | BTIG |
Silvan Tuerkcan | JMP Securities |
Rick Krause | Cantor Fitzgerald |
Eun Yang | Jefferies |
Sami Corwin | William Blair |
David Hoang | SMBC |
Yanan Zhu | Wells Fargo |
Welcome to the Taysha Gene Therapies, Fourth Quarter and full-year 2021 financial results and corporate update. At this time, all participants are in listen-only mode.
Following management's prepared remarks, we will hold a brief question-and-answer session.
As a reminder this call is being recorded today March 31st, 2022. I will now turn the call over to Dr.